Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis

Company Overview

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company combines drug candidates with proprietary delivery technologies intended to improve how therapies are administered, distributed, or released in the body.

Biodexa’s pipeline has included MTX110, a liquid formulation of the cancer medicine panobinostat being investigated for direct administration into brain tumors, including diffuse midline glioma. The company also has platform technologies designed to support long-acting injectable medicines, targeted drug delivery, and the formulation of compounds that can be difficult to administer using conventional methods.

The company was formerly known as Midatech Pharma plc and adopted the Biodexa Pharmaceuticals name as it broadened its development strategy. Biodexa is headquartered in the United Kingdom and has maintained operations and commercial-market activities connected with the United States. Its programs remain subject to clinical development and regulatory review, and the availability of specific products may change as the company advances or reprioritizes its pipeline.

Key Stats

• Today's Range: $0.65 to $0.69
• 50-Day Range: $0.66 to $2.13
• 52-Week Range: $0.61 to $59.40
• Volume: 103,286 shs
• Average Volume: 1.58 million shs
• Market Capitalization: $692.16 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Biodexa Pharmaceuticals Stock Analysis - MarketRank™

Biodexa Pharmaceuticals scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Biodexa Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Biodexa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Biodexa Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.50% of the float of Biodexa Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Biodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodexa Pharmaceuticals has recently increased by 715.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biodexa Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Biodexa Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.23

News Sentiment

Biodexa Pharmaceuticals has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Biodexa Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for BDRX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.

Percentage Held by Institutions

17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 9/10/2020
• Today: 9/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BDRX
• Previous Symbol: LON:MTPH
• CIK: 1643918
• Web: www.biodexapharma.com
• Phone: 441235888300
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.41
• Quick Ratio: 2.03

Sales & Book Value

• Annual Sales: $470 thousand
• Price / Sales: 1.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $110.30 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 1,030,000
• Free Float: 1,026,000
• Market Cap: $696.28 thousand
• Optionable: Not Optionable
• Beta: 1.18